• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

100例无BRCA1和BRCA2突变的日本家族性乳腺癌病例中RAD51C、PALB2和BRIP1的突变状态

Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.

作者信息

Sato Katsutoshi, Koyasu Mio, Nomura Sachio, Sato Yuri, Kita Mizuho, Ashihara Yuumi, Adachi Yasue, Ohno Shinji, Iwase Takuji, Kitagawa Dai, Nakashima Eri, Yoshida Reiko, Miki Yoshio, Arai Masami

机构信息

Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, Tokyo, Japan.

Translational Research Support, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

出版信息

Cancer Sci. 2017 Nov;108(11):2287-2294. doi: 10.1111/cas.13350. Epub 2017 Sep 18.

DOI:10.1111/cas.13350
PMID:28796317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5666035/
Abstract

In addition to BRCA1 and BRCA2, RAD51C, PALB2 and BRIP1 are known as breast cancer susceptibility genes. However, the mutation status of these genes in Japanese familial breast cancer cases has not yet been evaluated. To this end, we analyzed the exon sequence and genomic rearrangement of RAD51C, PALB2 and BRIP1 in 100 Japanese patients diagnosed with familial breast and ovarian cancer and without BRCA1 and BRCA2 mutations. We detected a large deletion from exons 6 to 9 in RAD51C, 4 novel BRIP1 missense variants containing 3 novel non-synonymous variants, c.89A>C, c.736A>G and c.2131A>G, and a splice donor site variant c.918+2T>C. No deleterious variant of PALB2 was detected. The results of pedigree analysis showed that the proband with a large deletion on RAD51C had a family history of both breast and ovarian cancer, and the families of probands with novel BRIP1 missense variants included a male patient with breast cancer or many patients with breast cancer within the second-degree relatives. We showed that the mutation frequency of RAD51C in Japanese familial breast cancer cases was similar to that in Western countries and that the prevalence of deleterious mutation of PALB2 was possibly lower. Furthermore, our results suggested that BRIP1 mutation frequency in Japan might differ from that in Western countries.

摘要

除了BRCA1和BRCA2之外,RAD51C、PALB2和BRIP1也被认为是乳腺癌易感基因。然而,这些基因在日本家族性乳腺癌病例中的突变状态尚未得到评估。为此,我们分析了100例被诊断为家族性乳腺癌和卵巢癌且无BRCA1和BRCA2突变的日本患者中RAD51C、PALB2和BRIP1的外显子序列及基因组重排情况。我们在RAD51C中检测到外显子6至9的大片段缺失,在BRIP1中检测到4个新的错义变异,其中包含3个新的非同义变异,即c.89A>C、c.736A>G和c.2131A>G,以及一个剪接供体位点变异c.918+2T>C。未检测到PALB2的有害变异。系谱分析结果显示,RAD51C存在大片段缺失的先证者有乳腺癌和卵巢癌家族史,携带BRIP1新错义变异的先证者家族中包括一名男性乳腺癌患者或二级亲属中有多名乳腺癌患者。我们发现,日本家族性乳腺癌病例中RAD51C的突变频率与西方国家相似,而PALB2有害突变的发生率可能较低。此外,我们的结果表明,日本BRIP1的突变频率可能与西方国家不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54a/5666035/8b372dd9bc32/CAS-108-2287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54a/5666035/8b372dd9bc32/CAS-108-2287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54a/5666035/8b372dd9bc32/CAS-108-2287-g001.jpg

相似文献

1
Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.100例无BRCA1和BRCA2突变的日本家族性乳腺癌病例中RAD51C、PALB2和BRIP1的突变状态
Cancer Sci. 2017 Nov;108(11):2287-2294. doi: 10.1111/cas.13350. Epub 2017 Sep 18.
2
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.基于人群的 BRCA1、BRCA2、RAD51C、RAD51D、BRIP1、PALB2 基因突变检测在未选择的普通人群女性中的成本效益。
J Natl Cancer Inst. 2018 Jul 1;110(7):714-725. doi: 10.1093/jnci/djx265.
3
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.在高危芬兰 BRCA1/2 种系突变阴性的乳腺癌和/或卵巢癌个体中筛查 BRCA1、BRCA2、CHEK2、PALB2、BRIP1、RAD50 和 CDH1 突变。
Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.
4
Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.阿根廷乳腺癌女性中 BRCA1、BRCA2、PALB2 和 RAD51C 种系致病性变异体。
Breast Cancer Res Treat. 2019 Dec;178(3):629-636. doi: 10.1007/s10549-019-05411-9. Epub 2019 Aug 24.
5
Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.非BRCA1/BRCA2乳腺癌患者中范可尼贫血基因杂合种系致病变异的频率:一项荟萃分析。
Breast Cancer Res Treat. 2020 Jul;182(2):465-476. doi: 10.1007/s10549-020-05710-6. Epub 2020 Jun 2.
6
Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.非 BRCA 遗传性乳腺癌和/或卵巢癌综合征患者的乳腺、输卵管和卵巢标本的病理学发现:携带 RAD51C、BARD1、BRIP1、PALB2、MUTYH 或 CHEK2 种系有害突变的 18 例患者的研究
Hum Pathol. 2017 Dec;70:14-26. doi: 10.1016/j.humpath.2017.06.018. Epub 2017 Jul 12.
7
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.对BRCA1/BRCA2基因阴性的中国早发性乳腺癌患者或有患病亲属的女性进行BRIP1/BACH1基因的突变分析。
Breast Cancer Res Treat. 2009 May;115(1):51-5. doi: 10.1007/s10549-008-0052-z. Epub 2008 May 16.
8
Retesting of women who are negative for a and mutation using a 20-gene panel.对 和 突变阴性的女性使用 20 基因检测panel 进行重复检测。
J Med Genet. 2020 Jun;57(6):380-384. doi: 10.1136/jmedgenet-2019-106403. Epub 2019 Nov 29.
9
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.高危非BRCA1/BRCA2乳腺癌家族中乳腺癌易感基因BRIP1 /BACH1/FANCJ的突变分析。
J Hum Genet. 2008;53(7):579. doi: 10.1007/s10038-008-0285-z. Epub 2008 Apr 15.
10
Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.BRIP1 和 PALB2 种系突变与犹太裔高癌症风险家族相关。
Fam Cancer. 2012 Sep;11(3):483-91. doi: 10.1007/s10689-012-9540-8.

引用本文的文献

1
and in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review).以及在精准肿瘤学中:与同源重组缺陷(HRD)相关的乳腺癌和卵巢癌的临床意义(综述)
Int J Oncol. 2025 Aug;67(2). doi: 10.3892/ijo.2025.5771. Epub 2025 Jul 4.
2
Treatment of ovarian cancer: From the past to the new era (Review).卵巢癌的治疗:从过去到新时代(综述)
Oncol Lett. 2025 Jun 3;30(2):384. doi: 10.3892/ol.2025.15130. eCollection 2025 Aug.
3
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.

本文引用的文献

1
mutation in a woman with bilateral breast cancer: A case report.一名双侧乳腺癌女性的基因突变:病例报告
Mol Clin Oncol. 2017 Apr;6(4):556-560. doi: 10.3892/mco.2017.1189. Epub 2017 Mar 9.
2
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.NCCN 指南解读:遗传/家族性高风险评估:乳腺和卵巢,2017 年第 2 版。
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20. doi: 10.6004/jnccn.2017.0003.
3
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.PALB2、CHEK2和ATM罕见变异与癌症风险:来自癌症遗传协会(COGS)的数据
考虑种系 BRCA1/2 突变状态的乳腺癌组织中同源重组修复(HRR)基因表达的改变。
Breast Cancer Res Treat. 2024 Dec;208(3):501-510. doi: 10.1007/s10549-024-07441-4. Epub 2024 Jul 30.
4
Biomarkers in Breast Cancer: An Old Story with a New End.乳腺癌生物标志物:旧故事的新结局。
Genes (Basel). 2023 Jun 28;14(7):1364. doi: 10.3390/genes14071364.
5
Targeted Sequencing of Germline Breast Cancer Susceptibility Genes for Discovering Pathogenic/Likely Pathogenic Variants in the Jakarta Population.对雅加达人群种系乳腺癌易感基因进行靶向测序以发现致病性/可能致病性变异
Diagnostics (Basel). 2022 Sep 16;12(9):2241. doi: 10.3390/diagnostics12092241.
6
Prognostic Value Estimation of BRIP1 in Breast Cancer by Exploiting Transcriptomics Data Through Bioinformatics Approaches.通过生物信息学方法利用转录组学数据评估BRIP1在乳腺癌中的预后价值
Bioinform Biol Insights. 2021 Nov 19;15:11779322211055892. doi: 10.1177/11779322211055892. eCollection 2021.
7
Breast Cancer Predisposition Genes and Synthetic Lethality.乳腺癌易感基因与合成致死性
Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.
8
Olaparib Monotherapy for -Mutated High-Grade Serous Endometrial Cancer.奥拉帕利单药治疗BRCA突变的高级别浆液性子宫内膜癌。
JCO Precis Oncol. 2020 Apr 9;4. doi: 10.1200/PO.19.00368. eCollection 2020.
9
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.BRIP1、RAD51C 和 RAD51D 突变与卵巢癌的高易感性相关:基于对约 30000 例病例的汇总分析的突变流行率和精确风险估计。
J Ovarian Res. 2020 May 2;13(1):50. doi: 10.1186/s13048-020-00654-3.
10
Germline breast cancer susceptibility gene mutations and breast cancer outcomes.胚系乳腺癌易感性基因突变与乳腺癌结局。
BMC Cancer. 2018 Mar 22;18(1):315. doi: 10.1186/s12885-018-4229-5.
J Med Genet. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. Epub 2016 Sep 5.
4
Hereditary breast and ovarian cancer: new genes in confined pathways.遗传性乳腺癌和卵巢癌:局限途径中的新基因。
Nat Rev Cancer. 2016 Sep;16(9):599-612. doi: 10.1038/nrc.2016.72. Epub 2016 Aug 12.
5
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.无证据表明BRIP1基因中的蛋白质截短变异与乳腺癌风险相关:对基因检测板检测的启示
J Med Genet. 2016 May;53(5):298-309. doi: 10.1136/jmedgenet-2015-103529. Epub 2016 Feb 26.
6
Human genetic variation database, a reference database of genetic variations in the Japanese population.人类遗传变异数据库,一个关于日本人群体遗传变异的参考数据库。
J Hum Genet. 2016 Jun;61(6):547-53. doi: 10.1038/jhg.2016.12. Epub 2016 Feb 25.
7
Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.BRCA1/2 突变阴性的韩国高危乳腺癌患者中 BRIP1 变异分析
Cancer Res Treat. 2016 Jul;48(3):955-61. doi: 10.4143/crt.2015.191. Epub 2016 Jan 19.
8
Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.多基因检测分析确定了乳腺癌和卵巢癌中DNA修复基因的种系突变。
Mol Genet Genomic Med. 2015 Sep;3(5):459-66. doi: 10.1002/mgg3.157. Epub 2015 May 12.
9
Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.155例日本乳腺癌和/或卵巢癌患者的PALB2基因突变分析。
Int J Clin Oncol. 2016 Apr;21(2):270-275. doi: 10.1007/s10147-015-0906-4. Epub 2015 Sep 28.
10
Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals.通过对1070名日本个体进行全基因组深度测序发现罕见变异。
Nat Commun. 2015 Aug 21;6:8018. doi: 10.1038/ncomms9018.